Exosome Diagnostics | Personalized Precision Healthcare

Skip to main content

Leveraging the proprietary Exosome Diagnostics technologies including total nucleic acid co-isolation (exoRNA and ctDNA), target capture and bioinformatics to yield unprecedented sensitivity and scope
Shahky: the world's first point of care exosomal protein capture and analysis instrument NO UP-FRONT SAMPLE PREP IS REQUIRED • Ten microliters of biofluid input • Label free detection • Fully automated - Four minute run time • High sensitivity and specificity (100x more sensitive than ELISA) • Small desktop footprint (12" x 16" x 18")
• First and only molecular test to rule out high-grade prostate cancer • Completely non-invasive, non-DRE, urine-based liquid biopsy test • Easy-to-interpret results
A to D Program We can drive the regulatory pathway to commercialize your assay.

News & Events

RECENT NEWS

September 19, 2017

Exosome Diagnostics and Chesapeake Urology Partner to Evaluate Clinical Value of ExoDx® Prostate(IntelliScore) in First Study Under Novel Evidence Development Collaboration

August 24, 2017

CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic Tests

August 9, 2017

Exosome Diagnostics Launches the MedOncAlyzer™ Pan-Cancer Panel

August 3, 2017

Exosome Diagnostics Achieves ISO 13485 Certification

August 1, 2017

Exosome Diagnostics Announces New World Headquarters and Laboratory in Waltham, MA

July 24, 2017

Exosome Diagnostics Completes $30 Million Series C Financing

June 22, 2017

Exosome Diagnostics Presents Breakthrough Liquid Biopsy Technologies at BIO International Convention

May 31, 2017

Exosome Diagnostics Will Demonstrate the “Shahky” Point of Care Protein Detection Instrument at American Society for Clinical Oncology

UPCOMING EVENTS

View more News and Events

Order Tests

Now available to Heathcare Providers for Clinical Use: The Industry’s First Exosome-Based Liquid Biopsy Tests

Order Here

The Industry’s First RNA-Based Liquid Biopsies

We are bringing the first exosome-based diagnostics to market. Learn more about our Laboratory Developed Tests, which will be analyzed in our CLIA-certified laboratory:

Follow Us on Twitter

Tweets by @ExosomeDx

© Exosome Diagnostics 2017